
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.
Read the full release






